KRAS Oncogenic Signaling Extends beyond Cancer Cells to Orchestrate the Microenvironment.

KRAS is one of the most frequently mutated oncogenes in cancer, being a potent initiator of tumorigenesis, a strong inductor of malignancy, and a predictive biomarker of response to therapy. Despite the large investment to understand the effects of KRAS activation in cancer cells, pharmacologic targeting of KRAS or its downstream effectors has not yet been successful at the clinical level. Recent studies are now describing new mechanisms of KRAS-induced tumorigenesis by analyzing its effects on the components of the tumor microenvironment. These studies revealed that the activation of KRAS on cancer cells extends to the surrounding microenvironment, affecting the properties and functions of its constituents. Herein, we discuss the most emergent perspectives on the relationship between KRAS-mutant cancer cells and their microenvironment components. Cancer Res; 78(1); 7-14. ©2017 AACR.

[1]  S. Sudarsanam,et al.  Expression of PD-L1 in colorectal cancer that lack mutations in RAS or TP53 genes. , 2017 .

[2]  T. Usui,et al.  Regulation of intestinal myofibroblasts by KRas-mutated colorectal cancer cells through heparin-binding epidermal growth factor-like growth factor. , 2017, Oncology reports.

[3]  N. Chen,et al.  KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma , 2017, Cancer Immunology, Immunotherapy.

[4]  E. Batlle,et al.  Determinants of metastatic competency in colorectal cancer , 2017, Molecular oncology.

[5]  Jian Su,et al.  Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma , 2016, Clinical Cancer Research.

[6]  Gabriela Kalna,et al.  ROCK signaling promotes collagen remodeling to facilitate invasive pancreatic ductal adenocarcinoma tumor cell growth , 2016, EMBO molecular medicine.

[7]  J. Gartner,et al.  T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. , 2016, The New England journal of medicine.

[8]  A. M. Houghton,et al.  Lung Cancer Subtypes Generate Unique Immune Responses , 2016, The Journal of Immunology.

[9]  E. Batlle,et al.  Targeting the Microenvironment in Advanced Colorectal Cancer. , 2016, Trends in cancer.

[10]  R. Kalluri.  The biology and function of fibroblasts in cancer , 2016, Nature Reviews Cancer.

[11]  M. Pittet,et al.  The role of myeloid cells in cancer therapies , 2016, Nature Reviews Cancer.

[12]  P. Hammerman,et al.  Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer. , 2016, JCI insight.

[13]  Mari Mino-Kenudson,et al.  PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes , 2016, Modern Pathology.

[14]  A. Mancuso,et al.  PD-1/PD-L1 expression and regorafenib clinical efficacy on refractory pancreatic cancer patient. , 2016 .

[15]  W. Arap,et al.  BCAM and LAMA5 Mediate the Recognition between Tumor Cells and the Endothelium in the Metastatic Spreading of KRAS-Mutant Colorectal Cancer , 2016, Clinical Cancer Research.

[16]  Crispin J. Miller,et al.  Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation , 2016, Cell.

[17]  F. McCormick.  K-Ras protein as a drug target , 2016, Journal of Molecular Medicine.

[18]  Jing Wang,et al.  STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. , 2016, Cancer research.

[19]  J. Berzofsky,et al.  Mutant KRAS Conversion of Conventional T Cells into Regulatory T Cells , 2016, Cancer Immunology Research.

[20]  Gary K. Schwartz,et al.  Tumour exosome integrins determine organotropic metastasis , 2015, Nature.

[21]  R. Klemke,et al.  Eukaryotic Translation Initiation Factor 5A (EIF5A) Regulates Pancreatic Cancer Metastasis by Modulating RhoA and Rho-associated Kinase (ROCK) Protein Expression Levels* , 2015, The Journal of Biological Chemistry.

[22]  L. Coussens,et al.  Myeloid Cells as Targets for Therapy in Solid Tumors. , 2015, Cancer journal.

[23]  Michael Peyton,et al.  Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. , 2015, Cancer discovery.

[24]  P. Storz,et al.  Inflammatory macrophages in pancreatic acinar cell metaplasia and initiation of pancreatic cancer , 2015, Oncoscience.

[25]  P. Storz.  The crosstalk between acinar cells with Kras mutations and M1-polarized macrophages leads to initiation of pancreatic precancerous lesions , 2015, Oncoimmunology.

[26]  A. Beggs,et al.  An immunogenomic stratification of colorectal cancer: Implications for development of targeted immunotherapy , 2015, Oncoimmunology.

[27]  Camille Stephan-Otto Attolini,et al.  Stromal gene expression defines poor-prognosis subtypes in colorectal cancer , 2015, Nature Genetics.

[28]  J. Wolchok,et al.  Immune Checkpoint Blockade in Cancer Therapy. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  S. Chang.  Tumorigenic Th17 cells in oncogenic Kras-driven and inflammation-accelerated lung cancer , 2015, Oncoimmunology.

[30]  V. Weaver,et al.  The extracellular matrix modulates the hallmarks of cancer , 2014, EMBO reports.

[31]  J. Willmann,et al.  Stromal response to Hedgehog signaling restrains pancreatic cancer progression , 2014, Proceedings of the National Academy of Sciences.

[32]  D. Radisky,et al.  Tumor Cell–Derived MMP3 Orchestrates Rac1b and Tissue Alterations That Promote Pancreatic Adenocarcinoma , 2014, Molecular Cancer Research.

[33]  A. Maitra,et al.  Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia. , 2014, Cancer cell.

[34]  R. Kalluri,et al.  Specific Activation of K-RasG12D Allele in the Bladder Urothelium Results in Lung Alveolar and Vascular Defects , 2014, PloS one.

[35]  D Saur,et al.  Oncogenic KRAS signalling in pancreatic cancer , 2014, British Journal of Cancer.

[36]  L. Robert.  Tumors perturbing extracellular matrix biosynthesis. The case of von Recklinghausen's disease. , 2014, Pathologie-biologie.

[37]  M. Caetano,et al.  T helper 17 cells play a critical pathogenic role in lung cancer , 2014, Proceedings of the National Academy of Sciences.

[38]  F. Giancotti.  Mechanisms Governing Metastatic Dormancy and Reactivation , 2013, Cell.

[39]  A. Salifoglou,et al.  Differential Expression of IL-17, 22 and 23 in the Progression of Colorectal Cancer in Patients with K-ras Mutation: Ras Signal Inhibition and Crosstalk with GM-CSF and IFN-γ , 2013, PloS one.

[40]  G. Capellá,et al.  The impact of KRAS mutations on VEGF-A production and tumour vascular network , 2013, BMC Cancer.

[41]  G. Capellá,et al.  The impact of KRAS mutations on VEGF-A production and tumour vascular network , 2013, BMC Cancer.

[42]  F. Couch,et al.  Loss of the Transcription Factor GLI1 Identifies a Signaling Network in the Tumor Microenvironment Mediating KRAS Oncogene-induced Transformation* , 2013, The Journal of Biological Chemistry.

[43]  R. Coffey,et al.  Proteomic Analysis of Exosomes from Mutant KRAS Colon Cancer Cells Identifies Intercellular Transfer of Mutant KRAS* , 2012, Molecular & Cellular Proteomics.

[44]  P. Jung,et al.  Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation. , 2012, Cancer cell.

[45]  N. Jhala,et al.  Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. , 2012, Cancer cell.

[46]  D. Spandidos,et al.  The tumor microenvironment in hepatocellular carcinoma (review). , 2012, International journal of oncology.

[47]  Sven Diederichs,et al.  The hallmarks of cancer , 2012, RNA biology.

[48]  J. Minna,et al.  Oncogenic KRAS‐induced interleukin‐8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non‐small cell lung cancer , 2012, International journal of cancer.

[49]  C. Galbán,et al.  Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. , 2012, The Journal of clinical investigation.

[50]  G. Feldmann,et al.  Ectopic overexpression of Sonic Hedgehog (Shh) induces stromal expansion and metaplasia in the adult murine pancreas. , 2011, Neoplasia.

[51]  M. Barbacid,et al.  Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. , 2011, Cancer cell.

[52]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[53]  William C Hines,et al.  Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression , 2011, Nature Medicine.

[54]  Laura La Paglia,et al.  Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. , 2010, Cancer treatment reviews.

[55]  M. Pino,et al.  Hypoxia Activates the K-Ras Proto-Oncogene to Stimulate Angiogenesis and Inhibit Apoptosis in Colon Cancer Cells , 2010, PloS one.

[56]  R. Steele,et al.  Activating K-Ras mutations outwith ‘hotspot’ codons in sporadic colorectal tumours – implications for personalised cancer medicine , 2010, British Journal of Cancer.

[57]  Richard O. Hynes,et al.  The Extracellular Matrix: Not Just Pretty Fibrils , 2009, Science.

[58]  P. Allavena,et al.  Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. , 2009, Carcinogenesis.

[59]  R. Vonderheide,et al.  Immunosurveillance of pancreatic adenocarcinoma: insights from genetically engineered mouse models of cancer. , 2009, Cancer letters.

[60]  P. M. Campbell,et al.  K-Ras Promotes Angiogenesis Mediated by Immortalized Human Pancreatic Epithelial Cells through Mitogen-Activated Protein Kinase Signaling Pathways , 2009, Molecular Cancer Research.

[61]  J. Pollard,et al.  Microenvironmental regulation of metastasis , 2009, Nature Reviews Cancer.

[62]  S. Steinberg,et al.  A Central Role for Foxp3+ Regulatory T Cells in K-Ras-Driven Lung Tumorigenesis , 2009, PloS one.

[63]  C. Der.  Faculty Opinions recommendation of Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. , 2008 .

[64]  Suzanne Schubbert,et al.  Hyperactive Ras in developmental disorders and cancer , 2007, Nature Reviews Cancer.

[65]  Jingwu Xie,et al.  Oncogenic KRAS Activates Hedgehog Signaling Pathway in Pancreatic Cancer Cells* , 2007, Journal of Biological Chemistry.

[66]  M. Hebrok,et al.  Hedgehog/Ras interactions regulate early stages of pancreatic cancer. , 2006, Genes & Development.

[67]  M. Beyer,et al.  Regulatory T cells in cancer. , 2006, Blood.

[68]  G. Tonon,et al.  K-ras activation generates an inflammatory response in lung tumors , 2006, Oncogene.

[69]  R. Offringa,et al.  Dual effect of KrasD12 knockdown on tumorigenesis: increased immune-mediated tumor clearance and abrogation of tumor malignancy , 2005, Oncogene.

[70]  Manish Gala,et al.  Induction of interleukin-8 preserves the angiogenic response in HIF-1α–deficient colon cancer cells , 2005, Nature Medicine.

[71]  J. Fleming,et al.  Molecular Consequences of Silencing Mutant K-ras in Pancreatic Cancer Cells: Justification for K-ras–Directed Therapy , 2005, Molecular Cancer Research.

[72]  D. Bar-Sagi,et al.  Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. , 2004, Cancer cell.

[73]  E. Voest,et al.  Stimulation of angiogenesis by Ras proteins. , 2004, Biochimica et biophysica acta.

[74]  D. Fukumura,et al.  Hypoxia-Induced Activation of p38 Mitogen-Activated Protein Kinase and Phosphatidylinositol 3′-Kinase Signaling Pathways Contributes to Expression of Interleukin 8 in Human Ovarian Carcinoma Cells , 2004, Clinical Cancer Research.

[75]  M. Barbacid,et al.  RAS oncogenes: the first 30 years , 2003, Nature Reviews Cancer.

[76]  J. Hancock,et al.  Ras proteins: different signals from different locations , 2003, Nature Reviews Molecular Cell Biology.

[77]  F. Brembeck,et al.  The mutant K-ras oncogene causes pancreatic periductal lymphocytic infiltration and gastric mucous neck cell hyperplasia in transgenic mice. , 2003, Cancer research.

[78]  M. Mareel,et al.  Role of Myofibroblasts at the Invasion Front , 2002, Biological chemistry.

[79]  D. Chung,et al.  Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia. , 2001, Cancer research.

[80]  R. Toftgård.  Hedgehog signalling in cancer , 2000, Cellular and Molecular Life Sciences CMLS.

[81]  S Weijzen,et al.  Modulation of the immune response and tumor growth by activated Ras , 1999, Leukemia.

[82]  J. Schlom,et al.  A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors. , 1999, Journal of immunotherapy.

[83]  W. L. Shupert,et al.  Identification of a human CD8+ T lymphocyte neo-epitope created by a ras codon 12 mutation which is restricted by the HLA-A2 allele. , 1998, Cellular immunology.

[84]  R. Kerbel,et al.  Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[85]  J. Schlom,et al.  Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations. , 1997, Cellular immunology.

[86]  K. Isselbacher,et al.  Early events of metastasis in the microcirculation involve changes in gene expression of cancer cells. Tracking mRNA levels of metastasizing cancer cells in the chick embryo chorioallantoic membrane. , 1997, The American journal of pathology.

[87]  L. Tentori,et al.  Dacarbazine-induced immunogenicity of a murine leukemia is attenuated in cells transfected with mutated K-ras gene. , 1997, Journal of experimental & clinical cancer research : CR.

[88]  R. Kerbel,et al.  Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. , 1995, Cancer research.

[89]  M J Bissell,et al.  How does the extracellular matrix direct gene expression? , 1982, Journal of theoretical biology.

[90]  M. Mino‐Kenudson,et al.  Programmed Cell Death Ligand 1 ( PD-L 1 ) Expression in Resected Lung Adenocarcinomas : Association with Immune Microenvironment , 2016 .

[91]  B. Necela,et al.  Mutant KRAS-induced expression of ICAM-1 in pancreatic acinar cells causes attraction of macrophages to expedite the formation of precancerous lesions. , 2015, Cancer discovery.

[92]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[93]  R. Seruca,et al.  KRAS signaling pathway alterations in microsatellite unstable gastrointestinal cancers. , 2010, Advances in cancer research.

[94]  Izhak Haviv,et al.  Co-evolution of tumor cells and their microenvironment. , 2009, Trends in genetics : TIG.

[95]  J. Downward.  Targeting RAS signalling pathways in cancer therapy , 2003, Nature Reviews Cancer.

[96]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[97]  Douglas Hanahan,et al.  Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment Prospects and Obstacles for Therapeutic Targeting of Function-enabling Stromal Cell Types , 2022 .